Ritobegron

DB12080InvestigationalSmall molecule

Ritobegron is under investigation in clinical trial NCT02256735 (Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin...

Mechanism: Pharmacologically active on Beta-3 adrenergic receptor
Curator reviewed
Formula / weight: C₂₁H₂₇NO₅ · 373.449 g/mol (avg)
Code names: KUC-7483

Resolves to

Compound

UNIILD86RKR53MCAS255734-04-4ChEMBLCHEMBL2107773PubChem9820882

Structure

InChIKeyVMMYRRFPMAGXNP-BTYIYWSLSA-NSMILESC[C@H](NCCC1=C(C)C=C(OCC(O)=O)C(C)=C1)[C@H](O)C1=CC=C(O)C=C1

Targets

P13945ADRB3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1,021Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ritobegron, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account